日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial

新辅助帕博西尼联合内分泌治疗与化疗治疗ER+/HER2-乳腺癌:一项随机II期试验

Matikas, Alexios; Tzoras, Evangelos; Sarafidis, Michail; Sifakis, Emmanouil G; Bjöhle, Judith; Barnekow, Elin; Margolin, Sara; Isaksson-Friman, Erika; Kessler, Luisa Edman; Zouzos, Athanasios; Johansson, Hemming; Hellström, Mats; Agartz, Susanne; Grybäck, Per; Salgkamis, Dimitrios; Zerdes, Ioannis; Wang, Kang; Hartman, Johan; Acs, Balazs; Sun, Wenwen; Boyaci, Ceren; Villacampa, Guillermo; Pascual, Tomas; Gavila, Joaquin; Prat, Aleix; Perou, Charles; Brandberg, Yvonne; Bergh, Jonas; Hatschek, Thomas; Foukakis, Theodoros

Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers.

抗 CSF-1R 疗法与免疫化疗相结合,可协调适应性免疫反应,以消除富含巨噬细胞的三阴性乳腺癌。

Pedroza Diego A, Yuan Xueying, Liu Fengshuo, Chan Hilda L, Zhang Christina, Bowie William, Smith Alex J, Calderon Sebastian J, Lieu Nadia, Wu Weiguo, Porter Paul, Sarkar Poonam, Zhao Na, Oehler Constanze V, Peller Ondrej, Gaber M Waleed, Zhu Qian, Perou Charles M, Zhang Xiang H-F, Rosen Jeffrey M

Identifying Locally Recurrent Versus Second Primary Breast Cancer: Genomic Versus Clinical Criteria from Carolina Breast Cancer Study Phase III

区分局部复发性乳腺癌和第二原发性乳腺癌:来自卡罗莱纳乳腺癌研究III期的基因组标准与临床标准

Van Alsten, Sarah C; Love, Michael I; Calhoun, Benjamin C; Butler, Eboneé N; Pfefferle, Adam D; Kirk, Erin L; Halloran, Christopher S; Zipple, Isaiah W; Perou, Charles M; Carey, Lisa A; Hoadley, Katherine A; Troester, Melissa A

MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9(+) monocyte-macrophage programming and durable anti-tumor immunity in triple negative breast cancer.

MERTK 抑制剂与免疫调节剂环磷酰胺协同作用,可诱导 CXCL9(+) 单核细胞-巨噬细胞编程,并在三阴性乳腺癌中产生持久的抗肿瘤免疫力。

Smith Alex J, Schrank Zachary, Guan Nan, Pedroza Diego A, Calderon Sebastian, Yuan Xueying, Zhao Na, Gabriel Zoe, Gao Yang, Rivas Charlotte, Liu Fengshuo, Serody Jonathan S, Perou Charles M, Earp H Shelton, Rosen Jeffrey M

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)

新辅助治疗期间残余病灶(RD)生物学和基因表达变化对HER2阳性早期乳腺癌(EBC)患者的预后价值

Fernandez-Martinez, A; Tanioka, M; Ahn, S G; Zagami, P; Pascual, T; Rediti, M; Tang, G; Hoadley, K A; Venet, D; Rashid, N U; Spears, P A; Di Cosimo, S; de Azambuja, E; Choudhury, A; Rastogi, P; Islam, M N; Cortes, J; Llombart-Cussac, A; Swain, S M; Sotiriou, C; Prat, A; Perou, C M; Carey, L A

Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer

整合蛋白质基因组学和正向遗传学揭示三阴性乳腺癌中一种新的有丝分裂脆弱性

Nicholas J Neill #,Shankha Satpathy #,Karsten Krug,Jitendra K Meena,Nivetha Ramesh Babu,Cheyenne Calderon,Desmon Reed,Marcus J Weber,Lacey E Dobrolecki,Alaina Lewis,Christina Sallas,Meenakshi Anurag ,Kimberly R Holloway,Chen Huang,Suhas Vasaikar,Maria F Cardenas,Beom-Jun Kim,Doug W Chan,Shayan C Avanessian,Siddhartha Tyagi,Mayra Orellana,Sufeng Mao,Heyuan Li,Fade Gong,Sarah J Kurley,Kristen L Meerbrey,Calla M Olson,Amritha Nair,Tingting Sun,Hsiang-Ching Chung,Elizabeth A Bowling,Jarey H Wang,Pengju Zhang,Peng Xiao,Duxiao Yang,Fabio Stossi,Mei-Yin C Polley,Alexander B Saltzman,Filip Mundt,D R Mani,Michael A Gillette,Susan G Hilsenbeck,George Miles,Carolina Gutierrez,C Kent Osborne,Charles Y Lin,Nathanael S Gray,Jinpeng Sun,David A Wheeler,Charles M Perou,Anna Malovannaya,Michael T Lewis ,Bing Zhang,Matthew J Ellis,Steven A Carr,Thomas F Westbrook

Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer

整合蛋白质基因组学和正向遗传学揭示三阴性乳腺癌中一种新的有丝分裂脆弱性

Nicholas J Neill # ,Shankha Satpathy # ,Karsten Krug ,Jitendra K Meena ,Nivetha Ramesh Babu ,Cheyenne Calderon ,Desmon Reed ,Marcus J Weber ,Lacey E Dobrolecki ,Alaina Lewis ,Christina Sallas ,Meenakshi Anurag ,Kimberly R Holloway ,Chen Huang ,Suhas Vasaikar ,Maria F Cardenas ,Beom-Jun Kim ,Doug W Chan ,Shayan C Avanessian ,Siddhartha Tyagi ,Mayra Orellana ,Sufeng Mao ,Heyuan Li ,Fade Gong ,Sarah J Kurley ,Kristen L Meerbrey ,Calla M Olson ,Amritha Nair ,Tingting Sun ,Hsiang-Ching Chung ,Elizabeth A Bowling ,Jarey H Wang ,Pengju Zhang ,Peng Xiao ,Duxiao Yang ,Fabio Stossi ,Mei-Yin C Polley ,Alexander B Saltzman ,Filip Mundt ,D R Mani ,Michael A Gillette ,Susan G Hilsenbeck ,George Miles ,Carolina Gutierrez ,C Kent Osborne ,Charles Y Lin ,Nathanael S Gray ,Jinpeng Sun ,David A Wheeler ,Charles M Perou ,Anna Malovannaya ,Michael T Lewis ,Bing Zhang ,Matthew J Ellis ,Steven A Carr ,Thomas F Westbrook

Corrigendum to "Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy" [Biomaterials 312 (2025) 122750

更正“纳米制剂TLR 7/8激动剂和PI3Kδ抑制剂对肿瘤微环境的免疫调节增强了放射疗法的治疗效果”[Biomaterials 312 (2025) 122750]

Yazdimamaghani, Mostafa; Kolupaev, Oleg V; Lim, Chaemin; Hwang, Duhyeong; Laurie, Sonia J; Perou, Charles M; Kabanov, Alexander V; Serody, Jonathan S

Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy.

纳米制剂 TLR 7/8 激动剂和 PI3k delta 抑制剂对肿瘤微环境进行免疫调节,可增强放射疗法的治疗效果

Yazdimamaghani Mostafa, Kolupaev Oleg V, Lim Chaemin, Hwang Duhyeong, Laurie Sonia J, Perou Charles M, Kabanov Alexander V, Serody Jonathan S

Progesterone receptor-dependent downregulation of MHC class I promotes tumor immune evasion and growth in breast cancer.

孕激素受体依赖性MHC I类分子下调促进乳腺癌肿瘤的免疫逃逸和生长

Tinoco Julio C, Saunders Harmony I, Werner Lauryn Rose, Sun Xiaopeng, Chowanec Eilidh I, Heard Amanda, Chalise Prabhakar, Vahrenkamp Jeffery M, Wilson Andrea E, Liu Cong-Xiao, Lei Gangjun, Wei Junping, Cros Hugo, Mohammed Hisham, Troester Melissa, Perou Charles, Markiewicz Mary A, Gertz Jason, Balko Justin M, Hartman Zachary Conrad, Hagan Christy R